Concord Biotech announced its Q2 financial results, highlighted by a ₹6,306.28 lakhs profit after tax. The board approved investing in Celliimune Biotech and a captive hybrid solar power project for its Limbasi plant. Revenue from operations stood at ₹24,705.75 lakhs, showcasing a robust financial performance for the quarter. The decisions signal a strategic move towards both business expansion and sustainable energy solutions.
Financial Performance Highlights
Concord Biotech reported a strong financial performance for the second quarter. Key figures include:
- Revenue from Operations: ₹24,705.75 lakhs
- Profit Before Tax: ₹8,551.75 lakhs
- Profit After Tax: ₹6,306.28 lakhs
These results reflect the company’s continued growth and effective operational strategies in the biotech sector. Q2 results highlight a solid performance compared to the previous financial year.
Investment in Celliimune Biotech
The Board approved an investment to acquire 100% equity share capital of M/s Celliimune Biotech Private Limited, marking a significant expansion move. The company plans to make the necessary disclosures upon the acquisition as per norms.
Captive Hybrid Solar Power Project
To promote sustainability and reduce energy costs, the Board approved an investment of up to ₹10 Crores in a Captive Hybrid Solar Power Project for the Limbasi Plant. This project reflects Concord Biotech’s commitment to environmentally responsible operations and infrastructure improvements.
Additional Financial Details
Other key figures from the financial statement include:
- Total Assets: ₹2,02,111.55 lakhs
- Total Equity: ₹1,82,525.93 lakhs
This indicates a strong asset base and equity position for Concord Biotech. These figures provide a holistic view of the company’s financial standing as of September 30, 2025.
Source: BSE
